Literature DB >> 28154411

Poor medication adherence in clinical trials: consequences and solutions.

Alasdair Breckenridge1, Jeffrey K Aronson2, Terrence F Blaschke3, Dan Hartman4, Carl C Peck5, Bernard Vrijens6.   

Abstract

Poor adherence to medicines in clinical trials can undermine the value of the trials; for example, by compromising estimates of the benefits and risks of a medicine. In this article, we highlight such consequences and also discuss approaches to tackle this problem.

Mesh：

Year:  2017        PMID： 28154411     DOI： 10.1038/nrd.2017.1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  18 in total

Review 1.  Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

Authors:  Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; Eric G Devine; David Hewitt; Mark P Jensen; Nathaniel P Katz; Amy A Kirkwood; Richard Malamut; John D Markman; Bernard Vrijens; Laurie Burke; James N Campbell; Daniel B Carr; Philip G Conaghan; Penney Cowan; Mittie K Doyle; Robert R Edwards; Scott R Evans; John T Farrar; Roy Freeman; Ian Gilron; Dean Juge; Robert D Kerns; Ernest A Kopecky; Michael P McDermott; Gwendolyn Niebler; Kushang V Patel; Richard Rauck; Andrew S C Rice; Michael Rowbotham; Nelson E Sessler; Lee S Simon; Neil Singla; Vladimir Skljarevski; Tina Tockarshewsky; Geertrui F Vanhove; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2019-12-13       Impact factor: 5.820

Review 2.  How the EMERGE guideline on medication adherence can improve the quality of clinical trials.

Authors:  Lina Eliasson; Sarah Clifford; Amy Mulick; Christina Jackson; Bernard Vrijens
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

Review 3.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

Review 4.  The need for increased pragmatism in cardiovascular clinical trials.

Authors:  Muhammad Shariq Usman; Harriette G C Van Spall; Stephen J Greene; Ambarish Pandey; Darren K McGuire; Ziad A Ali; Robert J Mentz; Gregg C Fonarow; John A Spertus; Stefan D Anker; Javed Butler; Stefan K James; Muhammad Shahzeb Khan
Journal:  Nat Rev Cardiol       Date:  2022-05-17       Impact factor: 49.421

5.  Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations.

Authors:  Nathaniel Katz; Robert H Dworkin; Richard North; Simon Thomson; Sam Eldabe; Salim M Hayek; Brian H Kopell; John Markman; Ali Rezai; Rod S Taylor; Dennis C Turk; Eric Buchser; Howard Fields; Gregory Fiore; McKenzie Ferguson; Jennifer Gewandter; Chris Hilker; Roshini Jain; Angela Leitner; John Loeser; Ewan McNicol; Turo Nurmikko; Jane Shipley; Rahul Singh; Andrea Trescot; Robert van Dongen; Lalit Venkatesan
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

6.  Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.

Authors:  Young Hee Nam; Colleen M Brensinger; Warren B Bilker; Charles E Leonard; Scott E Kasner; Tilo Grosser; Xuanwen Li; Sean Hennessy
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

7.  What do adult outpatients included in clinical trials know about the investigational drugs being assessed: A cross-sectional study in France.

Authors:  Clémentine Fronteau; Maxime Paré; Philippe Benoit; Sophie Tollec; Catherine Hamon; Vérane Schwiertz; Christian Maillard; Amélie Cransac; Christelle Volteau; Jean-François Huon; Véronique Burgeot; Martine Tching-Sin; Corinne Guérin; Laurent Flet
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

8.  The use of mechanistic evidence in drug approval.

Authors:  Jeffrey K Aronson; Adam La Caze; Michael P Kelly; Veli-Pekka Parkkinen; Jon Williamson
Journal:  J Eval Clin Pract       Date:  2018-06-11       Impact factor: 2.431

Review 9.  Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm.

Authors:  Marissa F Dockendorf; Bryan J Hansen; Kevin P Bateman; Matthew Moyer; Jyoti K Shah; Lisa A Shipley
Journal:  Clin Transl Sci       Date:  2020-11-30       Impact factor: 4.689

10.  Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study.

Authors:  Andrea Zimmer; Michael Coslovsky; Ivo Abraham; Bernhard F Décard
Journal:  Patient Prefer Adherence       Date:  2017-10-20       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.